Weight-loss surgery volumes fell over 20% (2022-2024) as GLP-1 drugs displace bariatric procedures

Weight-loss surgery in the US fell from more than 230,000 procedures in 2022 to a little more than 177,000 in 2024 — a 23% drop — according to research presented at an American Society for Metabolic and Bariatric Surgery (ASMBS) meeting, drawing on American College of Surgeons data from 2020 through 2024.¹ Lead researcher Tyler Cohn, an associate professor at Loyola University Medical Center, attributed the decline to "a surge in the use of GLP-1 medications" like Ozempic and Zepbound colliding with persistently high US obesity rates.¹ For medical-tourism bariatric clinics — a business built substantially around Mexican and other destinations offering gastric sleeve and bypass surgery at a fraction of US prices — that's a direct hit to the pipeline of patients who'd otherwise be searching for surgery abroad in the first place.

The decline shows up independently in insurance-claims data too

The ASMBS figures aren't an outlier. A separate, peer-reviewed study from researchers at Brigham and Women's Hospital, the Harvard T.H. Chan School of Public Health, and Brown University's School of Public Health — published in JAMA Network Open and led by Thomas C. Tsai — analyzed medical insurance claims from more than 17 million privately insured US adults, comparing the second half of 2022 against the second half of 2023.² It found bariatric surgery utilization fell 25.6% over that single year (from 0.22 to 0.16 surgeries per 1,000 patients with obesity), while GLP-1 receptor-agonist use over the same period rose 132.6% (from 1.89 to 4.41 patients per 1,000).² Even so, the study is a reminder of how small both numbers still are in absolute terms: 94.7% of the obese patients in the sample received neither treatment — GLP-1 drugs or surgery — during the study window, and only 0.3% underwent surgery at all.²

The two studies don't agree on the starting point, which is itself worth flagging rather than smoothing over: the ASMBS/ACS data behind the 23% decline cites "more than 230,000" bariatric procedures in 2022, while a STAT News report on the same JAMA study separately cites ASMBS as the source for a higher 2022 figure of 280,000 procedures.¹³ Both numbers are attributed to the same professional society, for the same year — a 50,000-procedure gap that most likely reflects different data cuts (all bariatric procedures vs. a narrower subset) rather than either figure being simply wrong, but it means even the "before" side of this decline isn't pinned to one agreed number.

What's actually shifting inside the surgery numbers

The ASMBS data also shows the mix of procedures changing, not just the total shrinking. Between 2020 and 2024, sleeve gastrectomy — the simpler, more common procedure — fell from 64% to 58% of all bariatric surgeries, while gastric bypass rose from 28% to 33%, its highest share in five years; procedure revisions also ticked up, from roughly 9% to 11%.¹ One reading of that shift is selection: as GLP-1 drugs absorb the more moderate-obesity patients who might previously have chosen the simpler sleeve procedure, the patients still choosing surgery skew toward more complex cases better suited to bypass, and toward patients returning for a revision of an earlier procedure.

Does a GLP-1 prescription actually replace a surgery long-term? The data disagrees with itself

The "displacement" story only holds up if GLP-1 drugs actually keep the weight off — and here the research is genuinely split depending on whether it's a controlled trial or real-world use. A systematic review and meta-regression of six randomized controlled trials covering 3,236 participants found that, on average, 60% of the weight lost during GLP-1 treatment was regained within one year of stopping, with modeled regain plateauing around 75% of the original loss.⁴ A separate real-world study from Cleveland Clinic, tracking 7,938 adult patients in Ohio and Florida who discontinued a GLP-1 drug and published in Diabetes, Obesity and Metabolism, found a far smaller effect: patients treated for obesity had lost an average of 8.4% of body weight before stopping, and had regained just 0.5% on average one year later — though that average masks real variation, since 55% of patients did gain some weight back while 45% kept losing or held steady.⁵

That gap between the controlled-trial number (60% regained) and the real-world number (0.5% regained on average) is large enough that it shouldn't be blended into one figure — the most likely explanation is that real-world patients who stop one GLP-1 drug frequently don't simply stop treatment altogether. In the Cleveland Clinic cohort, 27% switched to a different medication and 20% restarted their original one within 12 months of stopping, versus fewer than 1% who went on to have bariatric surgery.⁵ That last figure is arguably the most direct evidence for what destination bariatric clinics are actually up against: patients who discontinue a GLP-1 drug are, per this data, far more likely to cycle to a different drug than to convert into a surgery patient.

How Mexican bariatric clinics are repositioning around it

Mexico Bariatric Center, one of the larger US-facing bariatric-surgery-tourism operators, doesn't mention GLP-1 drugs by name on its own marketing pages — but its positioning has visibly shifted toward framing surgery as the durable alternative to a temporary drug regimen, describing gastric sleeve surgery as "the definitive metabolic reset" against what it characterizes as temporary pharmaceutical interventions, while pricing a gastric sleeve at $4,495–$4,695 against a stated US comparison of "a $20,000 price tag" — a roughly 77–82% discount by the clinic's own framing.⁶ Industry-marketing analysts covering the bariatric-tourism sector describe a broader version of the same pivot across the industry: patients who in 2022 might have searched "bariatric surgery near me" are now searching "how to get Ozempic" or "weight loss medication" first, meaning clinics that used to own that top-of-funnel search traffic are now competing for attention against "telehealth platforms with eight-figure ad budgets" as well as primary-care and obesity-medicine prescribers before a patient ever considers surgery.⁷ The same marketing analysis identifies a specific silver lining bariatric clinics are starting to target directly: patients who tried a GLP-1 drug and experienced insufficient results, side effects, weight regain, or affordability problems, which it describes as "a real and growing inbound segment for bariatric clinics" — a narrower, GLP-1-experienced patient pool rather than the broad new-patient funnel clinics relied on before 2022.⁷

The bottom line

The 23% US surgery-volume decline is real and shows up in two independently sourced datasets, even though those two sources can't agree on the exact 2022 baseline.¹²³ What's less settled is whether that decline represents permanent displacement or a temporary lull: the strongest available evidence that GLP-1 drugs and surgery aren't simply interchangeable is that real-world patients who stop taking a GLP-1 drug overwhelmingly cycle to another drug rather than to a bariatric surgeon's table.⁵ For medical-tourism bariatric clinics, that suggests the more durable competitive response is the one Mexico Bariatric Center's own marketing already reflects: positioning surgery specifically against a discontinued GLP-1 regimen's regain risk, rather than trying to compete with GLP-1 drugs on price or convenience while patients are still actively taking them.

Footnotes

1. https://www.cnyhealth.com/weight-loss-surgeries-fall-more-than-20-as-patients-turn-to-glp-1-meds/ ↩ ↩² ↩³ ↩⁴ ↩⁵

2. https://news.harvard.edu/gazette/story/2024/10/weight-loss-surgery-down-25-percent-as-anti-obesity-drug-use-soars ↩ ↩² ↩³ ↩⁴

3. https://www.statnews.com/2024/10/25/bariatric-surgery-falls-as-glp-1-demand-rises-wegovy-zepbound/ ↩ ↩²

4. https://pmc.ncbi.nlm.nih.gov/articles/PMC13043475/ ↩

5. https://newsroom.clevelandclinic.org/2026/03/12/what-happens-when-patients-stop-taking-glp-1-drugs-new-cleveland-clinic-study-reveals-real-world-insights ↩ ↩² ↩³

6. https://mexicobariatriccenter.com/ ↩

7. https://tandemmedicalmarketing.com/bariatric-surgery-marketing/ ↩ ↩²

Show all 7 sources